Liftstream is an executive search recruitment company in the life sciences sector
Prosensa begins FDA submission process for DMD drug
Authored by James Sheppard
Merck announces collaboration with Advaxis
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Advaxis, ADXS-PSA, Amsterdam Biotech, AstraZeneca, Cancer immunotherapy, clinical studies, Daniel O'Connor, David Mauro, Executive Director Oncology, Flanders Biotech, immunotherapy, MedImmune, Merck & Co, Orphan Drug, PD-1, pembrolizumab
Leave a comment
Celgene and BMS team up for cancer immunotherapy development
Authored by James Sheppard
Vaccibody successfully completes 35m NOK financing round
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Artic Securitites, cancer, Cancer immunotherapy, clinical studies, Datum and Partners, financing round, HPV 16, immunotherapy, malignancies caused by Human Papilloma Virus 16 (HPV16)., Medicon Valley, new share, Norway, Norwegian Cancer Society, oncology, Oslo Cluster, public markets, Vaccibody, VB1016
Leave a comment
Billionaires send Ganymed racing through clinic
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged ADC, Andreas Strungmann, ATS Beteiligungsverwaltung GmbH, BioRN, bispecific, clinical studies, Dr Ozlem Tureci, EMA, FDA, Ganymed, gastroesophageal cancer, Hexal, IMAB362, IMABs antibodies, Novartis, orphan drug designation, Professor Uger Sachin, Thomas Strungmann, venture capital
Leave a comment
Swedish Pharmalink receives Orphan Drug Approval for Busulipo
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Busulipo, cancer, clinical studies, clinical trials, EMA, FDA, funding, gold standard, hematopoietic stem cell transplantation, HSCT, Investinor, Johan Häggblad, Karolinska Institute, Medicon Valley, Nefecon, oncology, Orphan Drug, pharmacokinetics, Pharmalink Ab, primary IgA nephropathy, series C, sweden, venture capital
Leave a comment
AstraZeneca makes play in ADC market
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC Therapeutics, Antibody-drug conjugates, AstraZeneca, Auven Therapeutics, Bahija Jallal, Bind Therapeutics, biotech, cancer, clinical studies, Horizon, Horizon Discovery, MedImmune, Moderna Therapeutics, oncology, One Nucleus, ovarian carcinoma, Pascal Soriot, Phase III, SG2000, Spirogen, UK
Leave a comment
BrainStorms’s Cell Therapy receives Orphan Drug Designation in EU
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged ALS, Amyotrophic Lateral Sclerosis, BrainStorm, Brainstorm Cell Therapeutics, Cell Therapy, clinical studies, Dana-Fabre Cancer Institute, EMA, European Medicine Agency, FDA, Israel, multi-centre phase IIa trial, NurOwn, orphan drug designation, phase IIa clinical trials, Stem Cell Therapy
Leave a comment
Isis gains milestone from GSK for rare disease trial and Aegerion takes them on in HoFH
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Aegerion, antisense drugs, clinical studies, commercialisation, familial amyloid polyneuropathy, Genzyme, GSK, HoFH, homozygous familial hypercholesterolemia, Isis Pharmaceuticals, ISIS-TTRRX, Kynamro, milestone payments, Orphan drugs, phase 2/3 studies, rare diseases, transthyretin amyloidosis
Leave a comment